Keeping Up With the Evolving Landscape of CLL: Practical Solutions for Reducing Disparities in Rural and Underserved Communities

Advances in our understanding of chronic lymphocytic leukemia (CLL) biology have led to the identification of key biomarkers that inform treatment selection, while the emergence of targeted therapies has transformed clinical practice guidelines. Despite this progress, gaps in care remain—particularly in rural and underserved communities, where limited access to biomarker testing may result in suboptimal treatment decisions and outcomes. In addition, oncology workforce shortages, geographic and financial barriers, and low participation in clinical trials further contribute to disparities. This two-part CME/CE series highlights best practices in CLL management, including biomarker-guided therapy selection, optimal integration of novel agents, and patient-centered shared decision-making. Expert faculty will also discuss multidisciplinary approaches to enhance treatment adherence, adverse event management, and coordinated care in community oncology settings.